Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. University Hospital Gasthuisberg, Leuven, Belgium

Survival: 8.3 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: Belgium
City/State/Province: Leuven
Hospital: University Hospital Gasthuisberg
Journal: Link
Date: 8/2007

Patients: This phase II study involved 165 patients with stage III/IV or metastatic recurrent non-small-cell lung cancer. All had previously received a platinum-based therapy and about half had previously undergone radiation therapy. The patients ranged in age from 33 to 84 years, and the majority were men.

Treatment: All patients were given the chemotherapy drug Ixabepilone. The patients were divided into two study groups, or arms: arm A was given a single dose of the drug, and arm B was given the drug for 5 days.

Toxicity: Two patients died, one in each study arm. One death was due to pneumonia/respiratory failure; the other to pulmonary pneumonitis, infection, mucositis, confusion, and hypoxia. Grade 4 toxicities mainly affected white blood cells and occurred in 12% of patients or less. Two patients had grade 4 febrile neutropenia, one patient had grade 4 sensory neuropathy and one case of grade 4 dyspnea.

Results: The median overall survival in Arm 1 was 8.3 months and 7.3 months in Arm B. Twenty-two patients survived longer than two years.

Support: Authors received research funds from Bristol-Meyers Squibb, Eli Lilly & Co., EMD Pharmaceuticals, Imclone, GlaxoSmithKline, OSI Pharmaceuticals, AstraZeneca, and CTI Pharmaceuticals. Bristol-Meyers Squibb developed Ixabepilone.

Correspondence: Dr. Johan Vansteenkiste

E-mail to a Friend Email Physician More Information